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Abstract
Objective:  To  analyze  the  effects  of  treatment  approach  on  the  outcomes  of  newborns  (birth
weight [BW]  <  1,000  g)  with  patent  ductus  arteriosus  (PDA),  from  the  Brazilian  Neonatal
Research Network  (BNRN)  on:  death,  bronchopulmonary  dysplasia  (BPD),  severe  intraventricu-
lar  hemorrhage  (IVH  III/IV),  retinopathy  of  prematurity  requiring  surgical  (ROPsur),  necrotizing
enterocolitis  requiring  surgery  (NECsur),  and  death/BPD.
Methods:  This  was  a  multicentric,  cohort  study,  retrospective  data  collection,  including  new-
borns  (BW  <  1000  g)  with  gestational  age  (GA)  <  33  weeks  and  echocardiographic  diagnosis  of
PDA,  from  16  neonatal  units  of  the  BNRN  from  January  1,  2010  to  Dec  31,  2011.  Newborns  who
died  or  were  transferred  until  the  third  day  of  life,  and  those  with  presence  of  congenital  mal-
formation  or  infection  were  excluded.  Groups:  G1  --  conservative  approach  (without  treatment),
G2  -- pharmacologic  (indomethacin  or  ibuprofen),  G3  --  surgical  ligation  (independent  of  previ-
ous  treatment).  Factors  analyzed:  antenatal  corticosteroid,  cesarean  section,  BW,  GA,  5  min.
Apgar  score  <  4,  male  gender,  Score  for  Neonatal  Acute  Physiology  Perinatal  Extension  (SNAPPE
II),  respiratory  distress  syndrome  (RDS),  late  sepsis  (LS),  mechanical  ventilation  (MV),  surfac-
tant  (<  2  h  of  life),  and  time  of  MV.  Outcomes:  death,  O2 dependence  at  36  weeks  (BPD36wks),
IVH  III/IV,  ROPsur,  NECsur,  and  death/BPD36wks. Statistics:  Student’s  t-test,  chi-squared  test,  or
Fisher’s  exact  test;  Odds  ratio  (95%  CI);  logistic  binary  regression  and  backward  stepwise  mul-
tiple  regression.  Software:  MedCalc  (Medical  Calculator)  software,  version  12.1.4.0.  p-values  <
0.05  were  considered  statistically  signiﬁcant.
Results:  1,097  newborns  were  selected  and  494  newborns  were  included:  G1  -  187  (37.8%),  G2
-  205  (41.5%),  and  G3  -  102  (20.6%).  The  highest  mortality  was  observed  in  G1  (51.3%)  and  the
lowest  in  G3  (14.7%).  The  highest  frequencies  of  BPD36wks (70.6%)  and  ROPsur were  observed  in
G3  (23.5%).  The  lowest  occurrence  of  death/BPD36wks occurred  in  G2  (58.0%).  Pharmacological
(OR 0.29;  95%  CI:  0.14-0.62)  and  conservative  (OR  0.34;  95%  CI:  0.14-0.79)  treatments  were
protective  for  the  outcome  death/BPD36wks.
Conclusion:  The  conservative  approach  of  PDA  was  associated  to  high  mortality,  the  surgical
approach to  the  occurrence  of  BPD36wks and  ROPsur,  and  the  pharmacological  treatment  was
protective  for  the  outcome  death/BPD36wks.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
PALAVRAS-CHAVE
Prematuridade;
Muito  baixo  peso;
Ligadura cirúrgica;
Canal arterial
Efeitos  da  abordagem  terapêutica  da  persistência  de  canal  arterial  sobre  a  evoluc¸ão
neonatal  de  recém-nascidos  de  extremo  baixo  peso
Resumo
Objetivo:  Analisar  os  efeitos  da  terapêutica  adotada  para  o  canal  arterial  (CA)  em  recém-
nascidos (RN)  <  1.000gadmitidos  em  unidades  neonatais  (UN)  da  Rede  Brasileira  de  Pesquisas
Neonatais  (RBPN),  sobre  os  desfechos:  óbito,  displasia  broncopulmonar  (DBP),  hemorragia
intraventricular  grave  (HIVIII/IV),  retinopatia  da  prematuridade  cirúrgica  (ROPcir),  enterocolite
necrosante  cirúrgica  (ECNcir)  e  o  desfecho  combinado  óbito  e  DBP.
Métodos: Estudo  multicêntrico,  de  coorte,  coleta  de  dados  retrospectiva,  incluindo  RN  de  16
Este é um artigo Open Access sob a licença de CC BY-NC-NDUN  da  RBPN  de  01/01/2010  a  31/12/2011,  PN  <  1.000  g,  idade  gestacional  (IG)  <  33  semanas
e  diagnóstico  ecocardiográﬁco  de  PCA.  Excluídos:  óbitos  ou  transferências  até  o  terceiro  dia
de  vida,  infecc¸ões  congênitas  ou  malformac¸ões.  Grupos:  G1  --  conservadora  (sem  intervenc¸ão
medicamentosa ou  cirúrgica),  G2  --  farmacológica  (indometacina  ou  ibuprofeno)  e  G3  --  cirúrgico
(com  ou  sem  tratamento  farmacológico  anterior).  Analisou-se:  uso  de  esteroide  antenatal,  parto
cesárea,  PN,  IG,  Apgar5’  <  4,  sexo  masculino,  SNAPPE  II,  síndrome  do  desconforto  respiratório
618  Sadeck  LS  et  al.
(SDR),  sepse  tardia,  ventilac¸ão  mecânica  (VM),  surfactante  <  2  horas  de  vida,  tempo  de  VM
e  os  desfechos:  óbito,  dependência  de  oxigênio  com  36  semanas  (DBP36s),  HIV  III/IV,  ROPcir,
ECNcir e  óbito/DBP36s.  Estatística:  Teste  t-Student,  Qui-Quadrado  ou  teste  Exato  de  Fisher.
Testes  de  Regressão  Binária  Logística  e  Regressão  Múltipla  Stepwise  Backward.  MedCalc  (Medical
Calculator)  software,  versão  12.1.4.0.p  <  0,05.
Resultados:  Foram  selecionados  1.097  RN  e  494  foram  incluídos:  G1-187  (37,8%),  G2-205  (41,5%)
e G3-102  (20,6%).  Veriﬁcou-se:  maior  mortalidade  (51,3%)  no  G1  e  menor  no  G3(14,7%);  maior
frequência  DBP36s (70,6%)  e  ROPcir (23,5%)  no  G3;  maior  frequência  de  óbito/DBP36s no  G2
(58,0%).  As  abordagens  farmacológica  (OR-0,29;  95%,  IC-0,14-0,62)  e  conservadora  (OR-0,34;
95%,  IC-  0,14-0,79)  foram  protetoras  somente  para  o  desfecho  óbito/DBP36sem.
Conclusão:  Em  RN  com  PCA,  a  abordagem  conservadora  relacionou-se  à  maior  mortalidade,
a cirúrgica  à  ocorrência  de  DBP36s e  ROPcir.,  enquanto  o  tratamento  farmacológico  mostrou-se
protetor para  o  desfecho  óbito/DBP36sem.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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of mechanical  ventilation,  and  surfactant  administration  up
to 2  hours  of  life;  and  primary  outcomes:  death,  oxygen
dependence at  36  weeks  (BPD36wks),  IVH  III/IV  according  to
ste é ntroduction
he  approach  of  patent  ductus  arteriosus  (PDA)  in  the  neona-
al period  has  been  widely  discussed  in  the  literature,  both
egarding the  best  time  to  detect  it,  as  well  as  the  conduct  to
e used  in  the  presence  of  DA,  particularly  in  preterm  new-
orns (PNBs)  of  low  birth  weight,  considering  its  implications
or the  evolution  of  these  newborns.
While  the  DA  is  an  essential  structure  during  the
ntrauterine period,  responsible  for  the  deviation  of  the  pul-
onary circulation  to  the  aorta  and  maintaining  the  fetal
ystemic blood  ﬂow,  its  persistence  after  birth  may  trigger
 series  of  events,  culminating  with  heart  failure.1 Particu-
arly in  infants  with  birth  weight  (BW)  below  1,000  g,  patent
uctus arteriosus  (PDA)  with  hemodynamic  effects  may  be
ssociated with  greater  morbimortality,2 resulting  in  higher
isks of  heart  failure,  duration  of  mechanical  ventilation,
ronchopulmonary dysplasia  (BPD),3 intraventricular  hem-
rrhage (IVH),4 and  necrotizing  enterocolitis  (NEC).5
However,  a  considerable  percentage  of  PDAs  will  close
pontaneously,6,7 or  may  remain  patent  without  causing
igniﬁcant symptoms.7 Consequently,  early  start  of  the
reatment may  unnecessarily  expose  NBs  to  prostaglandin
nhibitors or  surgical  ductus  ligation,  which  are  associated
ith adverse  effects.8 This  situation  might  be  prevented  if
reterm infants  more  likely  to  undergo  spontaneous  PDA
losure are  identiﬁed.
Conduct  related  to  the  management  of  PDA  in  PNBs  has
een highly  variable  in  the  literature,  resulting  in  many  stud-
es, especially  in  infants  with  birth  weight  (BW)  <  1,000  g.8
To  date,  there  is  not  enough  evidence  to  deﬁne  the
est approach  to  PDA  in  PNBs.9--11 Although  pharmacological
reatment with  indomethacin  or  ibuprofen  has  been  proven
ffective in  PDA  closure,  no  improvement  was  observed  in
volution when  the  following  events  were  analyzed:  death,
PD, and  necrotizing  enterocolitis  (NEC).  Most  published
linical trials  focused  on  PDA  closure  with  pharmacological
r surgical  approach.12
Considering  the  current  knowledge  and  existing  ques-
Eions on  the  treatment  option  to  be  used  in  the  presence
f PDA,  whether  conservative,  pharmacological,  or  surgi-
al, the  present  study  aimed  to  assess  the  effects  of  these
pproaches in  infants  weighing  less  than  1,000  g  admitted
t
b
Io  neonatal  intensive  care  units  (NICUs)  of  the  Brazilian
eonatal Research  Network  (BNRN)  in  2010  and  2011,  on  the
ccurrence of  the  following  outcomes:  death,  BPD,  severe
ntraventricular hemorrhage  (IVH  III/IV),  retinopathy  of  pre-
aturity requiring  surgery  (ROPsur),  necrotizing  enterocolitis
equiring surgery  (NECsur),  and  the  combined  outcome  of
eath and  BPD.
ethods
 multicenter,  cohort  study  was  performed  with  retrospec-
ive data  from  BNRN,  which  included  infants  admitted  at  16
NRN NICUs  from  January  1st,  2010  to  December  31st,  2011.
The  newborns  were  selected  according  to  the  following
nclusion criteria:  BW:  400-999  g,  gestational  age  (GA)  <  33
eeks, and  echocardiographic  diagnosis  of  PDA,  regardless
f hemodynamic  effects.  Newborns  who  died  or  were  trans-
erred up  to  the  third  day  of  life  and  those  diagnosed  with
ongenital infections  or  malformations  were  excluded.
The  NBs  included  in  the  study  were  divided  into  study
roups according  to  the  therapeutic  management  of  PDA:
1 -  conservative  approach  (without  medication  or  surgical
ntervention), G2  - pharmacological  approaches  (treatment
ith indomethacin  or  ibuprofen),  and  G3  -  surgical  approach
surgical ligation,  regardless  of  whether  or  not  the  NB  had
reviously received  prostaglandin  inhibitor).
The  variables  analyzed  were  perinatal  conditions:  use  of
ntenatal steroids  and  Cesarean  delivery;  birth  conditions:
irth weight,  gestational  age,  adequate  birth  weight  for  ges-
ational  age,  considering  small  for  gestational  age  (SGA)  as
NBs with  weight  below  the  5th  percentile  of  the  Alexander
t al.13 curve,  Apgar  5  min.  <  4,  and  male  gender;  neona-
al outcome:  Score  for  Neonatal  Acute  Physiology  Perinatal
xtension (SNAPPE  II)  risk  score,  respiratory  distress  syn-
rome (RDS),  late-onset  neonatal  sepsis  (LONS)  (positive
lood culture),  need  for  mechanical  ventilation,  duration
um artigo Open Access sob a licença de CC BY-NC-NDhe classiﬁcation  of  Papille,  ROPsur, NECsur,  and  the  com-
ined outcome  death/BPD36wks.
This  study  was  approved  by  the  Ethics  Committee  of  the
nstitution (Ethics  Committee  for  Research  Project  Analysis
ith  
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uTherapeutic  approach  on  extreme  low  birth  weight  infants  w
of  the  Clinical  Board  of  Hospital  das  Clínicas  and  Faculdade
de Medicina  da  Universidade  de  São  Paulo)  through  research
protocol 1383/09  and  later  adopted  by  the  other  institu-
tions.
Statistical  Analysis
Categorical  data  are  shown  with  frequency  distribution,
and continuous  data  using  mean  and  standard  deviation,  as
indicated. The  univariate  analysis  of  categorical  variables
used the  chi-squared  or  Fisher’s  exact  test,  when  indicated,
whereas Student’s  t-test  was  used  for  continuous  varia-
bles. To  calculate  the  risk,  after  determining  the  odds  ratio
(95% CI),  logistic  binary  regression  and  backward  stepwise
multiple regression  were  performed  using  MedCalc  (Medi-
cal Calculator)  software,  version  12.1.4.0.  The  statistical
signiﬁcance level  was  set  at  5%  (p  <  0.05).
Results
A  total  of  1,097  newborns  with  BW  =  400  to  999  g  and  GA
< 33  weeks  were  admitted  in  16  NICUs  of  the  BNRN  dur-
ing the  study  period.  Of  these,  220  were  excluded  due  to
death or  transfer  during  the  ﬁrst  three  days  of  life,  malfor-
mations, and  congenital  infections;  494  newborns  met  the
inclusion criteria  with  echocardiographic  diagnosis  of  PDA
and  no  information  regarding  the  presence  of  symptoms.
The  infants  were  subdivided  according  to  the  therapeutic
approach, into:  G1  -  187  (37.8%),  G2  -  205  (41.5%),  and  G3  -
102 (20.6%)  (Fig.  1).
The  characteristics  of  the  population  according  to  each
study group  is  shown  in  Table  1;it  can  be  observed  that  there
were differences  between  the  groups  in  relation  to  the  GA,
mean SNAPPE  II  score,  frequency  and  time  of  mechanical
ventilation, and  occurrence  of  LONS.
Regarding  the  analyzed  outcomes,  it  was  observed  that
mortality was  higher  in  G1  (51.3%),  while  it  was  lower  in
G3 (14.7%).  The  highest  incidence  of  BPD36wks (70.6%)  and
ROPsur (23.5%)  was  observed  in  G3,  while  the  combined
outcome death/BPD36wks was  less  frequent  in  G2  (58.0%).  It
was not  possible  to  analyze  the  effects  of  the  therapy  used
on the  occurrence  of  NECsur,  due  to  the  very  small  number
of cases,  although  a  statistically  signiﬁcant  difference  was
observed between  G1  and  G2  (Table  2).
The  multivariate  regression  analysis  showed  no  inﬂuence
of the  type  of  therapeutic  approach  on  the  probability  of
death or  the  occurrence  of  BPD36wks alone,  rather  only  for  the
combined outcome  death/BPD36wks.  However,  the  following
were identiﬁed  as  risk  factors  for  the  outcome  of  death:
NECsur (OR  5.64,  95%  CI:  1.03  to  30.7)  and  IVH-III/IV  (OR
3.62, 95%  CI:  1.30  to  10.11).  For  the  male  gender  (OR  2.59,
95% CI:  1.33  to  5.02),  LONS  (OR  1.88,  95%  CI:  1.00  to  3.54),
GA (OR  1.49,  95%  CI:  1.22  to  1.81),  and  time  of  MV  (OR  1.04,
95% CI:  1.02  to  1.07)  were  factors  related  to  the  presence
of BPD36wks.  BW  alone  was  a  protective  factor  against  the
outcomes death  and  BPD36wks (OR  0.99,  95%  CI:  0.99  to  0.99)
(Table 3).Regarding the  combined  outcome  of  death/BPD36wks,
the following  were  identiﬁed  as  risk  factors:  male  gender
(OR 3.24,  95%  CI:  1.73  to  6.18)  and  LONS  (OR  2.53,  95%
CI: 1.42  to  4.52),  while  the  protective  factors  were:
e
i
a
cpatent  ductus  arteriosus  619
harmacological  treatment  (OR  0.29,  95%  CI:  0.14  to  0.62),
onservative approach  (OR  0.34,  95%  CI:  0.14  to  0.79),  and
W (OR  0.99,  95%  CI:  0.99  to  0.99).
iscussion
he  survival  of  preterm  infants  without  sequelae  has  been
he objective  of  perinatal  care  of  these  at-risk  NBs.  Among
he factors  that  may  inﬂuence  their  evolution,  PDA  has
een considered  a  risk  factor  with  important  consequences.
herefore, the  need  to  deﬁne  a  therapeutic  approach  in
he presence  of  PDA  that  can  ensure  greater  control  of
hese complications  has  increased,  particularly  in  infants
ith lower  BW.
In  the  present  study,  conducted  with  NBs  weighing  less
han 1,000  g  at  birth  and  with  PDA,  the  protection  of  con-
ervative and  pharmacological  treatments  for  the  combined
utcome death/BPD36wks was  demonstrated,  although  the
onservative treatment  was  related  to  higher  mortality.
ale gender  was  also  identiﬁed,  together  with  LONS,  GA,
nd time  of  mechanical  ventilation,  as  factors  associated
ith the  presence  of  BPD36wks.  The  death  outcome  was  asso-
iated with  the  presence  of  NECsur and  IVH  III/IV.
The  infants  included  in  this  study,  although  constituting  a
roup at  high  risk  for  the  events  analyzed  herein,  as  they  had
n average,  less  than  28  weeks  of  gestational  age  and  BW
ower than  800  grams,  might  have  had  this  risk  attenuated,
ecause two-thirds  of  them  received  antenatal  corticoste-
oids and  were  born  with  good  vital  signs.  In  the  postnatal
eriod, although  more  than  90%  developed  RDS  and  required
echanical ventilation,  approximately  70%  received  surfac-
ant within  2  hours  of  life.  However,  the  occurrence  of  LONS
n approximately  half  of  the  newborns  may  have  contributed
o the  higher  frequencies  BPD36wks, especially  in  G3,  which
orresponded to  65.7%  of  the  NBs.
Due  to  the  high  frequency  of  antenatal  corticosteroid  use
n the  analyzed  groups,  with  no  difference  between  them,
t was  not  possible  to  assess  the  inﬂuence  of  these  drugs  on
he analyzed  outcomes.
Considering  the  study  groups,  it  was  observed  that  they
iffered in  relation  to  GA,  which  was  lower  in  the  group  that
equired surgical  ligation  of  the  PDA,  which  also  showed
 higher  frequency  of  late-onset  sepsis,  characterizing  a
igher risk  of  BPD36wks and  ROPsur, according  to  the  results
btained. Nevertheless,  higher  mortality  was  observed  in
he group  receiving  conservative  treatment,  which  proba-
ly explains  the  lower  frequency  of  the  other  complications
n this  group,  and  the  option  for  non-pharmacological  or
urgical treatment  due  to  clinical  conditions  of  the  NBs.
he group  that  received  pharmacological  treatment  had  the
owest SNAPPE  II  score,  which  characterizes  lower  risk  of
orbimortality and  also,  possibly,  the  occurrence  of  the
ssessed outcomes.
In  general,  the  treatment  of  PDA  shows  a  wide  variation
etween services,  especially  due  to  the  lack  of  consistent
ata regarding  the  best  clinical  approach.  It  remains
nclear whether  there  are  advantages  among  the  several
xisting proposals  in  the  literature:  prophylactic  treatment
n children  under  a  speciﬁc  gestational  age;  early  treatment
t symptom  onset,  or  later  when  the  PDA  has  signiﬁ-
ant hemodynamic  effects,  in  relation  to  the  immediate
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NBs with GA < 33 weeks 
BW 400 to 999 grams in 
16 NICUs of BNRN 
(n = 1,097 NBs)
Period: 2010 to 2011 
Group I  
n = 187 (37.8%) 
PDA Treatment: 
Conservative
Group III 
n = 102 (20.6%) 
PDA Treatment: Surgical
Ligation, regardless of 
pharmacological 
treatment  
Maternal data: ANCS, C-section delivery
Characteristics of NB: Apgar 5 min. < 4, BW, GA, male gender, SNAPPE II
Evolution: RDS, surfactant within up to 2 hours of life, MV, time of MV, late sepsi s
Group II  
n = 205 (41.5%) 
PDA Treatment: 
Pharmacologica l
indomethacin or 
ibuprofen 
Groups I, II, III 
Outcomes: 
Mortality 
O2 dependence with 36  
weeks (BPD36wks)
IVH III/IV 
ROPsur
NECsur
Combined outcome: 
death/BPD36wks
PDA diagnosis (ECHO) 
n = 494 NBs 
Excluded: 220 NBs 
Death or transfer < 3 days, 
malformations, and/or 
congenital infections 
Figure  1  Study  design.
BNRN,  Brazilian  Neonatal  Research  Network;  PDA  (ECHO),  patent  ductus  arteriosus  diagnosed  by  echocardiogram;  ANCS,  antenatal
corticosteroids;  BW,  birth  weight;  GA,  gestational  age;  SNAPPE  II,  Score  for  Neonatal  Acute  Physiology  Perinatal  Extension;  RDS,
respiratory  distress  syndrome;  MV,  mechanical  ventilation;  BPD,  bronchopulmonary  dysplasia;  IVH  III/IV,  intraventricular  hemorrhage
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Brade  III/IV;  ROPsur,  retinopathy  of  prematurity  with  surgical  pr
linical  effects  and  long-term  results,  particularly  regarding
PD.8,14--17 However,  there  are  potential  complications  of
he pharmacological  treatment  of  PDA,  such  as  renal  dys-
unction and  intestinal  perforation,  as  well  as  those  arising
rom surgical  ligation,  such  as  cardiopulmonary  dysfunction.
In  this  study,  comparing  the  three  forms  of  therapeu-
ic approach,  it  can  be  observed  that  infants  treated
ith prostaglandin  inhibitors  (indomethacin  or  ibuprofen)
d
a
t
iure;  NECsur,  necrotizing  enterocolitis  with  surgical  procedure.
emonstrated  less  BPD,  ROPsur,  NECsur, and  death/BPD36wks,
specially when  compared  to  those  who  underwent  surgi-
al ligation.  When  we  considered  the  outcomes  death  and
PD36wks separately,  the  type  of  medical  or  surgical  approach
id not  inﬂuence  them,  while  conservative  treatment  was
ssociated with  higher  mortality.  However,  in  the  analysis  of
he combined  outcome  (death/BPD36wks),  the  pharmacolog-
cal and  conservative  treatments  were  protective  factors.
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Table  1  Birth  status  and  in-hospital  evolution  of  the  population,  according  to  the  study  groups,  between  2010  and  2011.
Characteristics  G1
n  =  187
G2
n =  205
G3
n =  102
p
G1 x  G2
p
G1 x  G3
p
G2 x  G3
ANCS  130  (69.5)  161  (78.5)  70  (68.6)  0.054a 0.981a 0.079a
C-section  121  (64.7)  136  (66.3)  59  (57.8)  0.815a 0.306a 0.183a
Mean  BW  (g)
(SD)
772.0 (142.3)  804  (121.6)  781.0  (118.5)  0.017  0.555  0.117
Mean GA  in
weeks (SD)
27.6 (2.2)  27.4  (1.9)  26.6  (1.8)  0.307  <  0.001  <  0.001
Male gender  n
(%)
91 (48.7) 90 (43.9) 48  (47.1) 0.399a 0.890a 0.688a
Apgar  5  min.  <
4  n  (%)
13 (6.9)  3  (1.5)  3  (2.9)  0.013b 0.247b 0.615b
SGA  <  5%  n  (%)  49  (26.2)  32  (15.6)  13  (12.7)  0.013a 0.012a 0.619a
Mean  SNAPPE  II
(SD)
43 (22.1)  34  (18.6)  40  (19.5)  <  0.001  0.177  0.026
RDS
n (%)
167 (89.3)  182  (88.8)  95  (93.1)  0.996a 0.391a 0.314a
LONS  n  (%)  83  (44.4)  95  (46.3)  67  (65.7)  0.7741 <  0.001a 0.002a
Surfactant  <2  h
n (%)
118 (63.1)  140  (68.3)  66  (64.7)  0.329a 0.886a 0.616a
MV  n  (%)  171  (91.4)  195  (95.1)  101  (99.0)  0.159a 0.007a 0.107a
Mean  time  of
MV (days)
(SD)
16.8 (20.1)  20.4  (20.7)  44.8  (32.4)  0.044  <  0.001  <  0.001
ANCS, maternal use of antenatal corticosteroids; BW, birth weight; GA, gestational age; SGA < 5%, birth weight below the 5th percentile%
of the Alexander et al.13 curve; SNAPPE II, Score for Neonatal Acute Physiology Perinatal Extension; SD, standard deviation; RDS, respira-
tory distress syndrome; LONS, late-onset neonatal sepsis conﬁrmed by positive blood culture; surfactant < 2 h, surfactant administration
within 2 hours of life; MV, need for mechanical ventilation.
a Chi-squared test.
b Fisher’s exact test.
Table  2  Univariate  analysis  of  outcomes  analyzed  according  to  the  studied  groups.
Outcomes  G1
n  =  187
G2
n =  205
G3
n =  102
p
G1 x  G2
p
G1  x  G3
p
G2  x  G3
Death  n  (%)  96  (51.3)  58  (28.3)  15  (14.7)  <0.001a <  0.001a 0.013a
BPD36wks n  (%)  48  (25.7)  65  (31.7)  72  (70.6)  0.227a <  0.001a <  0.001a
IVH  III/IV  n  (%)  37  (19.8)  35  (17.1)  23  (22.5)  0.573a 0.688a 0.317a
ROPsur n  (%)  10  (5.3)  16  (7.8)  24  (23.5)  0.417b <  0.001b <  0.001b
NECsur n  (%)  14  (7.5)  3  (1.5)  5  (4.9)  0.005b 0.465b 0.120b
Death/BPD36wks
n  (%)
134  (71.6)  119  (58.0)  83  (81.4)  0.007a 0.098a <  0.001a
BPD36wks, bronchopulmonary dysplasia with oxygen dependence at 36 weeks corrected by gestational age; IVH III/IV, intraventricular
hemorrhage  grade III and IV; ROPsur, retinopathy of prematurity requiring surgical intervention; NECsur, necrotizing enterocolitis requiring
h and
l
e
r
t
t
csurgical intervention; Death/BPD36wks, combined outcome of deat
a Chi-squared test.
b Fisher’s exact test.
These  ﬁndings  agree  with  those  of  Mirea  et  al.16 who,
using multivariate  analyses,  toattempt  to  adjust  for  treat-
ment selection  bias,  provided  evidence  of  an  association
between surgical  ligation  of  PDA  and  increased  neonatal
mortality or  severe  morbidity,  but  conversely,  found  no
effect of  treatment  with  indomethacin  when  compared  to
conservative treatment.
Based on  the  above  considerations,  the  present  ﬁndings
suggest greater  protection  for  the  outcomes  analyzed  in
the group  treated  pharmacologically,  although  there  are
m
r
p
m BPD36wks.
imitations  in  this  analysis,  mainly  regarding  the  number  of
xcluded cases  and  the  non-homogeneous  distribution  of
isk factors  among  the  groups,  which  did  not  allow  assigning
he results  only  to  the  therapeutic  option.  Another  aspect
o be  considered  is  the  lack  of  information  concerning  the
linical manifestations  of  PDA  and  the  age  at  which  treat-
ent was  established,  as  well  as  the  possible  differences
egarding treatment  indications  in  the  NICUs.  Regarding  the
rotection related  to  BW,  as  its  OR  was  close  to  1,  it  had
inimal impact  on  the  assessed  outcomes.
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Table  3  Risk  factors  identiﬁed  for  outcomes  analyzed  by  backward  stepwise  multiple  regression.
Outcome  Variable  OR  (95%  CI)  p
Death  BW  0.99  (0.99-0.99)  0.0401
NECsur 5.64  (1.03-30.7)  0.0455
IVH III/IV  3.62  (1.30-10.11)  0.0139
BPD36wks BW  0.99  (0.99-0.99)  0.0207
Male gender  2.59  (1.33-5.02)  0.0048
LONS 1.88  (1.00-3.54) 0.0484
GA  1.49  (1.22-1.81) 0.0001
MV  duration 1.04  (1.02-1.07) < 0.0001
Death/BPD36wks Pharmacological  Treatment  0.29  (0.14-0.62)  0.0012
Conservative Treatment  0.34  (0.14-0.79)  0.0123
BW 0.99  (0.99-0.99)  0.0001
Male gender  3.24  (1.73-6.18)  0.0002
LONS 2.53  (1.42-4.52)  0.0017
NECsur, necrotizing enterocolitis requiring surgical intervention; IVH III/IV, intraventricular hemorrhage grade III and IV; BPD36wks, bron-
chopulmonary dysplasia with oxygen dependence at 36 weeks of corrected gestational age; BW, birth weight; GA, gestational age at
birth; MV duration, duration of mechanical ventilation; Death/BPD36wks, combined outcome of death or bronchopulmonary dysplasia
with oxygen dependence at 36 weeks of corrected gestational age; LONS, late-onset neonatal sepsis; OR, odds ratio; CI, conﬁdence
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Even  with  the  aforementioned  limitations,  these  ﬁnd-
ngs indicate  the  need  to  conduct  more  randomized
ontrolled studies  to  evaluate  the  possible  protective
ffect of  pharmacological  treatment  in  high-risk  NBs  with
DA.
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